Myeloma Canada is pleased to announce that as of December 11, 2023, Health Canada has granted Notice of Compliance Information with conditions (NOCc) for elranatamab (Elrexfio). 

Elrexfio (elranatamab solution for injection) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. 

Click here to consult the Product information (canada.ca)